Predicting Response to Pembrolizumab in Non-Small-Cell Lung Cancer by Analyzing the Spatial Arrangement of Tumor-Infiltrating Lymphocytes (TILs) Using Deep Learning

*Efrat Ofek[1], *Jair Bar[2], Alona Zer[3], Damien Urban[2], Chen Mayer[1], Chen Sade Zaltz[4], Ori Zelichov[5], Alon Groisman[5], Avi Laniado[5], Yuval Gabay[5], Willy Polychenko[5], Roman Gluskin[5], Albert Achtenberg[5], Meora Feinmesser[4], Iris Barshack[1] [6]

[1]Department of Pathology, Sheba Medical Center, Ramat Gan, Israel; [2]Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel; [3]Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; [4]Department of Pathology, Rabin Medical Center, Petah Tikva, Israel; [5]Nucleai, Tel Aviv, Israel; [6]Tel-Aviv University, Tel-Aviv, Israel
*The two authors contributed equally to this work

Abstract No: 9045

INTRODUCTION

- Only a small proportion of Non-Small-Cell-Lung-Cancer (NSCLC) patients derive durable benefit from treatment with immune checkpoint inhibitors (ICI)

- PD-L1 score is the only approved biomarker to select NSCLC patients for treatment with single-agent ICI, however, its predictive value is limited

- The spatial arrangement of immune cells in the tumor microenvironment (TME), emerges as a potential biomarker for ICI efficacy in NSCLC

- We utilized deep-learning (DL) models to extract TME features from digitized H&E slides and evaluated their predictive role in patients with NSCLC treated with Pembrolizumab

METHODS

- NSCLC patients (n=92) treated with single-agent 1st line pembrolizumab in two medical centers were identified

- 49 patients from one center were used for training, and 43 patients from another center were used for validation

- Pre-treatment H&E whole slide images were analyzed using a deep-learning model to identify and classify tumor cells, TILs, tumor and stromal areas, and spatial features were calculated

- We used 1-year overall survival (OS) to determine durable clinical benefit; spatial and clinical features were combined to train a binary classifier that identifies patients with a favorable clinical outcome

- The classifier was then applied to the validation set and differences in OS between patients with positive and negative scores were assessed

RESULTS

- The trained classifier combined three spatial features, such as the average proximity between tumor cells and TILs, as well as three clinical features

- Median score was used to determine positive or negative patients

- In a cross-validation on the training set, patients with positive score had a significantly higher median OS (mOS) than patients with negative score (HR=0.43, 95% CI 0.22-0.83;p=0.01)

- The classifier was then applied to the validation set, dividing patients to either positive (n=18) or negative (n=25) scores

- Baseline patient characteristics and PD-L1 score were similar between the positive and negative groups.

- In a Kaplan-Meier (KM) analysis, OS was significantly higher in patients with a positive score compared to patients with a negative score (HR=0.35, 95% CI 0.13-0.98; p<0.05).

- **Positive patients had a significantly higher median OS (NR vs.17.8m, p<0.05) and 2-year OS (70.8% vs. 33%, p=0.02) than negative patients.**

KM analysis of the training set
HR=0.43 (95% CI 0.22-0.83; p=0.01)

Positive Score (mOS=22.2m)
Negative Score (mOS=4.8m)

No. at Risk
Positive Score 24 19 12 6 3 0
Negative Score 25 11 5 3 2 0

KM analysis of the validation set
HR=0.35 (95% CI 0.13-0.98; p<0.05)

Positive score (mOS=NR)
Negative score (mOS=17.8m)

No. at Risk
Positive score   18 13 10 7 1 0
Negative Score   25 13   7 2 1 0

RESULTS (Continued)

- PD-L1 scores were similar between patients with positive and negative DL-based spatial scores (p=0.9)

CONCLUSIONS

- Deep-learning models that analyze the TME from H&E whole-slide images can identify NSCLC patients with durable benefit on Pembrolizumab.

- Identifying NSCLC patients who are exceptionally sensitive to anti-PD-1 therapy as monotherapy may improve clinical decision making and spare patients the unnecessary adverse effects associated with the addition chemotherapy or another IO agent.

Corresponding Authors: Efrat.Ofek@sheba.health.gov.il, Yair.Bar@sheba.health.gov.il